Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo extends life in aggressive lung cancer

NCT ID NCT03043872

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tested adding the immunotherapy drug durvalumab (with or without another drug, tremelimumab) to standard chemotherapy for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 987 participants received either chemo alone or chemo plus the immunotherapy combination. Results showed that adding durvalumab helped people live longer compared to chemo alone. This approach aims to control the disease and improve survival, but it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

987 people

The number who actually took part.

Started

Mar 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Histologically or cytologically documented extensive disease. Brain metastases; must be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment. 2. Suitable to receive a platinum-based chemotherapy regimen as 1st line treatment. 3. Life expectancy ≥12 weeks at Day 1. 4. ECOG 0 or 1 at enrolment. 5. No prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines. Exclusion criteria: 1. Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest). 2. Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS 3. Active infection including tuberculosis, HIV, hepatitis B anc C 4. Active or prior documented autoimmune or inflammatory disorders 5. Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung carcinoma extensive disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung carcinoma extensive disease

Contacts and locations

Locations

  • Research Site

    Birmingham, Alabama, 35235, United States

  • Research Site

    Scottsdale, Arizona, 85259, United States

  • Research Site

    Rogers, Arkansas, 72758, United States

  • Research Site

    Santa Monica, California, 90404, United States

  • Research Site

    New Haven, Connecticut, 06520, United States

  • Research Site

    Athens, Georgia, 30607, United States

  • Research Site

    Fort Wayne, Indiana, 46804, United States

  • Research Site

    Muncie, Indiana, 47303, United States

  • Research Site

    Leawood, Kansas, 66209, United States

  • Research Site

    Wichita, Kansas, 67214, United States

  • Research Site

    Paducah, Kentucky, 42003, United States

  • Research Site

    Grand Rapids, Michigan, 49503, United States

  • Research Site

    Mineola, New York, 11501, United States

  • Research Site

    Cleveland, Ohio, 44106, United States

  • Research Site

    Columbus, Ohio, 43219, United States

  • Research Site

    Harrisburg, Pennsylvania, 17109, United States

  • Research Site

    Sioux Falls, South Dakota, 57104, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Kennewick, Washington, 99336, United States

  • Research Site

    Buenos Aires, C1118AAT, Argentina

  • Research Site

    Ciudad de Buenos Aires, C1426, Argentina

  • Research Site

    Mar del Plata, 7600, Argentina

  • Research Site

    Rosario, 2000, Argentina

  • Research Site

    San Miguel de Tucumán, T4000IAK, Argentina

  • Research Site

    Linz, 4021, Austria

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Vienna, 1210, Austria

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Curitiba, 81520-060, Brazil

  • Research Site

    Passo Fundo, 99010 260, Brazil

  • Research Site

    Porto Alegre, 91350-200, Brazil

  • Research Site

    Ribeirão Preto, 14048-900, Brazil

  • Research Site

    Rio de Janeiro, 22793-080, Brazil

  • Research Site

    Salvador, 41.950-610, Brazil

  • Research Site

    Santo André, 09060-650, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 03102-002, Brazil

  • Research Site

    Panagyurishte, 4500, Bulgaria

  • Research Site

    Plovdiv, 4000, Bulgaria

  • Research Site

    Plovdiv, 4004, Bulgaria

  • Research Site

    Sofia, 1330, Bulgaria

  • Research Site

    Sofia, 1431, Bulgaria

  • Research Site

    Sofia, 1618, Bulgaria

  • Research Site

    Sofia, 1784, Bulgaria

  • Research Site

    Varna, 9010, Bulgaria

  • Research Site

    Beijing, 100142, China

  • Research Site

    Beijing, 100730, China

  • Research Site

    Beijing, 100853, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changchun, 130021, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chongqing, 400038, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310006, China

  • Research Site

    Hangzhou, 310009, China

  • Research Site

    Hefei, 230601, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Nanjing, 210029, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Shanghai, 200433, China

  • Research Site

    Shenyang, 110042, China

  • Research Site

    Ürümqi, 830000, China

  • Research Site

    Wenzhou, 325000, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Xi'an, 710038, China

  • Research Site

    Xi'an, 710061, China

  • Research Site

    Zhanjiang, 524001, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Zhuhai, 519099, China

  • Research Site

    Brno, 639 00, Czechia

  • Research Site

    Olomouc, 775 21, Czechia

  • Research Site

    Ostrava - Vitkovice, 703 84, Czechia

  • Research Site

    Prague, 128 08, Czechia

  • Research Site

    Prague, 140 59, Czechia

  • Research Site

    Prague, CZ-150 18, Czechia

  • Research Site

    Avignon, 84918, France

  • Research Site

    Brest, 29609, France

  • Research Site

    Créteil, 94010, France

  • Research Site

    La Tronche, 38043, France

  • Research Site

    Pierre-Bénite, 69310, France

  • Research Site

    Rennes, 35033, France

  • Research Site

    Aachen, 52074, Germany

  • Research Site

    Berlin, 13125, Germany

  • Research Site

    Gauting, 82131, Germany

  • Research Site

    Gera, 07548, Germany

  • Research Site

    Hamburg, 20251, Germany

  • Research Site

    Heidelberg, 69126, Germany

  • Research Site

    Mainz, 55131, Germany

  • Research Site

    Regensburg, 93053, Germany

  • Research Site

    Budapest, 1083, Hungary

  • Research Site

    Budapest, 1106, Hungary

  • Research Site

    Budapest, 1121, Hungary

  • Research Site

    Budapest, 1134, Hungary

  • Research Site

    Deszk, 6772, Hungary

  • Research Site

    Gyula, 5700, Hungary

  • Research Site

    Kaposvár, 7400, Hungary

  • Research Site

    Kecskemét, 6000, Hungary

  • Research Site

    Miskolc, 3529, Hungary

  • Research Site

    Pécs, 7624, Hungary

  • Research Site

    Székesfehérvár, 8000, Hungary

  • Research Site

    Jerusalem, 91031, Israel

  • Research Site

    Kfar Saba, 95847, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Bergamo, 24127, Italy

  • Research Site

    Meldola, 47014, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Palermo, 90146, Italy

  • Research Site

    Roma, 00100, Italy

  • Research Site

    Terni, 05100, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Fukuoka, 812-8582, Japan

  • Research Site

    Fukushima, 960-1295, Japan

  • Research Site

    Himeji-shi, 670-8520, Japan

  • Research Site

    Iwakuni-shi, 740-8510, Japan

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Kōtoku, 135-8550, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Kyoto, 606-8507, Japan

  • Research Site

    Matsuyama, 791-0280, Japan

  • Research Site

    Nagoya, 464-8681, Japan

  • Research Site

    Nagoya, 466-8560, Japan

  • Research Site

    Okayama, 700-8558, Japan

  • Research Site

    Sakaishi, 591-8555, Japan

  • Research Site

    Sayama, 589-8511, Japan

  • Research Site

    Tokushima, 770-8503, Japan

  • Research Site

    Ube-shi, 755-0241, Japan

  • Research Site

    Yokohama, 236-0004, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Amsterdam, 1066 CX, Netherlands

  • Research Site

    Arnhem, 6815 AD, Netherlands

  • Research Site

    Groningen, 9713 GZ, Netherlands

  • Research Site

    Hengelo, 7555 DL, Netherlands

  • Research Site

    Maastricht, 6202 AZ, Netherlands

  • Research Site

    Rotterdam, 3015 GD, Netherlands

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Bialystok, 15-540, Poland

  • Research Site

    Lublin, 20-954, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Cluj-Napoca, 400015, Romania

  • Research Site

    Floreşti, 407280, Romania

  • Research Site

    Suceava, 720237, Romania

  • Research Site

    Moscow, 105229, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Rostov-on-Don, 344037, Russia

  • Research Site

    Saint Petersburg, 194291, Russia

  • Research Site

    Saint Petersburg, 195271, Russia

  • Research Site

    Saint Petersburg, 196603, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Ufa, 450054, Russia

  • Research Site

    Banská Bystrica, 97517, Slovakia

  • Research Site

    Bardejov, 085 01, Slovakia

  • Research Site

    Bratislava, 82606, Slovakia

  • Research Site

    Bratislava, 833 01, Slovakia

  • Research Site

    Košice, 041 91, Slovakia

  • Research Site

    Nové Zámky, 940 01, Slovakia

  • Research Site

    Trnava, 91708, Slovakia

  • Research Site

    Changwon, 51353, South Korea

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Daegu, 42415, South Korea

  • Research Site

    Incheon, 21565, South Korea

  • Research Site

    Jinju, 660-702, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seongnam-si, 463-712, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 110746, South Korea

  • Research Site

    A Coruña, 15006, Spain

  • Research Site

    Badajoz, 06008, Spain

  • Research Site

    Badalona, 08916, Spain

  • Research Site

    Barcelona, 08041, Spain

  • Research Site

    Madrid, 08035, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Santander, 39008, Spain

  • Research Site

    Valencia, 46010, Spain

  • Research Site

    Zaragoza, 50009, Spain

  • Research Site

    Changhua, 50006, Taiwan

  • Research Site

    Kaohsiung City, 82445, Taiwan

  • Research Site

    Kaohsiung City, 83301, Taiwan

  • Research Site

    Taichung, 40447, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Tainan, 736, Taiwan

  • Research Site

    Taipei, 11217, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Ankara, 06230, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Edirne, 22030, Turkey (Türkiye)

  • Research Site

    Istanbul, 32098, Turkey (Türkiye)

  • Research Site

    Izmir, 35100, Turkey (Türkiye)

  • Research Site

    Izmir, 35620, Turkey (Türkiye)

  • Research Site

    Dnipro, 49102, Ukraine

  • Research Site

    Ivano-Frankivsk, 76018, Ukraine

  • Research Site

    Kirovohrad, 25006, Ukraine

  • Research Site

    Kryvyi Rih, 50048, Ukraine

  • Research Site

    Kyiv, 03022, Ukraine

  • Research Site

    Kyiv, 03115, Ukraine

  • Research Site

    Lviv, 79031, Ukraine

  • Research Site

    Odesa, 65055, Ukraine

  • Research Site

    Sumy, 40022, Ukraine

  • Research Site

    Vinnytsia, 21029, Ukraine

  • Research Site

    Zaporizhzhia, 69040, Ukraine